Abstract:Abstract Chemokine receptor CXCR4 overexpression in solid tumors has been strongly associated with poor prognosis and adverse clinical outcome. However, blockade of CXCL12-CXCR4 signaling axis by inhibitors like Nox-A12, FDA approved CXCR4 inhibitor drug AMD3100 have shown limited clinical success in cancer treatment. Therefore, exclusive contribution of CXCR4-CXCL12 signaling in pro-tumorigenic function is questionable. In our pursuit to understand the impact of chemokine signaling in carcinogenesis, we reveal that instead of CXCR4-CXCL12 signaling, presence of CXCR4 intracellular protein augments paclitaxel resistance and pro-tumorigenic functions. In search of pro-apoptotic mechanisms for CXCR4 mediated drug resistance; we discover that DR5 is a new selective target of CXCR4 in breast and colon cancer. Further, we detect that CXCR4 directs the differential recruitment of transcription factors p53 and YY1 to the promoter of DR5 in course of its transcriptional repression. Remarkably, inhibiting CXCR4-ligand-mediated signals completely fails to block the above phenotype. Overexpression of different mutant versions of CXCR4 lacking signal transduction capabilities also result in marked downregulation of DR5 expression in colon cancer indeed confirms the reverse relationship between DR5 and intracellular CXCR4 protein expression. Irrespective of CXCR4 surface expression, by utilizing stable gain and loss of function approaches, we observe that intracellular CXCR4 protein selectively resists and sensitizes colon cancer cells against paclitaxel therapy in vitro and in vivo. Finally, performing TCGA data mining and using human breast cancer patient samples, we demonstrate that expression of CXCR4 and DR5 are inversely regulated. Together, our data suggest that targeting CXCR4 intracellular protein may be critical to dampen the pro-tumorigenic functions of CXCR4.

CXC chemokine receptor 4 (CXCR4) blockade in cancer treatment

CXCL12-CXCR4/CXCR7 Axis in Colorectal Cancer: Therapeutic Target in Preclinical and Clinical Studies

The CXCL12 (SDF-1)/CXCR4 Chemokine Axis: Oncogenic Properties, Molecular Targeting, and Synthetic and Natural Product CXCR4 Inhibitors for Cancer Therapy.

The Role of the CXCL12/CXCR4/CXCR7 Chemokine Axis in Cancer

CXCR4-Targeted Radiopharmaceuticals for the Imaging and Therapy of Malignant Tumors

Chemokine Receptor CXCR4: an Important Player Affecting the Molecular-Targeted Drugs Commonly Used in Hematological Malignancies.

A review on CXCR4/CXCL12 axis in oncology: No place to hide

CXCL12 / CXCR4 / CXCR7 chemokine axis and cancer progression

Epigenetic regulation of CXCR4 signaling in cancer pathogenesis and progression

CXCL12/CXCR4: a symbiotic bridge linking cancer cells and their stromal neighbors in oncogenic communication networks

Drug Design Targeting the Cxcr4/Cxcr7/Cxcl12 Pathway

CXCR4 intracellular protein promotes drug resistance and tumorigenic potential by inversely regulating the expression of Death Receptor 5

Potential of CXCR4/CXCL12 Chemokine Axis in Cancer Drug Delivery

The molecular mechanism of CXCR4/SDF-1 in tumor signal transduction

CXCR4 inhibition in human pancreatic and colorectal cancers induces an integrated immune response

C-X-C Motif Chemokine Receptor 4–Targeted Radioligand Therapy in Hematological Malignancies—Myeloablative Effects, Antilymphoma Activity, and Safety Profile

Oncogenic roles and drug target of CXCR4/CXCL12 axis in lung cancer and cancer stem cell

Chemokine-chemokine Receptor Pathway As a Tumor Therapeutic Target: the Significance of SDF-1CXCR4 Pair

Research progress about CXCR4 and tumor

Role of CXCL12/CXCR4 Signaling Axis in Pancreatic Cancer.

Potential Role of CXCR4 Targeting in the Context of Radiotherapy and Immunotherapy of Cancer